Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of masitinib in mild to moderate Alzheimer's disease
MOH_2017-05-21_000447Phase 3Active, not recruiting
- Sponsor
- AB Science
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of masitinib in Alzheimer's disease (AD) (5 arms), sponsored by AB Science. Started May 2017; status: active, not recruiting.
02
Drugs
masitinib
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on MOH_2017-05-21_000447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-21_000447.